We are aware of a supply issue with Ozempic, which has been largely driven by off-label use for weight loss. We have issued guidance in the form of Medicine Supply Notifications and, on 18 July, issued a National Patient Safety Alert which made it clear that Ozempic, which is solely licensed to treat Type 2 diabetes, should only be used for that purpose, and should not be routinely prescribed for weight loss. We have engaged with relevant regulators, and the General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have issued a joint statement stressing the importance of health and care professionals meeting regulatory standards. We have also added Ozempic and other glucagon-like peptide 1 receptor agonists to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom. We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for UK patients, for example by asking suppliers to expedite deliveries. We have provided advice for healthcare professionals on how to manage patients requiring this medicine whilst there are shortages and are keeping this under review as the situation evolves. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.